ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Tezepelumab Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
January 08, 2021Amgen and AstraZeneca announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo.
Pharma Sources Insight July 2025
